Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, announced the appointment of Mr. Youchen Chen, Chief Financial Officer, and Dr. Ian Y. Liu, Senior Vice President and Global Head of Legal, as Executive Directors of the Company, effective immediately. The appointments further strengthen the alignment between the Company's Board of Directors and management team, providing strong leadership support for the Company's global strategic execution and sustainable growth.
Mr. Youchen Chen, Chief Financial Officer and Executive Director of Harbour BioMed, stated: "It is a great honor to further participate in corporate governance and strategic decision-making in my new capacity as Executive Director. Since joining Harbour BioMed, I have had the privilege of witnessing and contributing to the Company's rapid global development and the execution of multiple key strategic partnerships. In the future, I look forward to working closely with the Board and the management team to further optimize the Company's financial and capital market strategies and drive long-term value creation, while contributing to Harbour BioMed's ambitious goal of becoming a leading global platform-based biopharmaceutical group by 2028."